Solriamfetol-based solutions for agricultural, livestock, athletic, and cognitive applications

Publication ID: 24-11857528_0002_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Solriamfetol-based solutions for agricultural, livestock, athletic, and cognitive applications,” Published Technical Disclosure No. 24-11857528_0002_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857528_0002_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,528.

Summary of the Inventive Concept

The inventive concept leverages the core technology of solriamfetol therapy to develop novel applications in agriculture, livestock, athletics, and cognitive enhancement, addressing unmet needs in these fields.

Background and Problem Solved

The original patent focused on solriamfetol therapy for subjects with impaired renal function, primarily targeting excessive daytime sleepiness. However, the technology's potential extends beyond this scope. The new inventive concept addresses the limitations of the original patent by exploring novel applications that capitalize on solriamfetol's benefits.

Detailed Description of the Inventive Concept

The inventive concept comprises four primary applications: (1) a system for monitoring and managing agricultural crop yields, utilizing solriamfetol to promote plant growth; (2) a method for optimizing livestock feed formulations, adjusting solriamfetol content based on renal function to enhance feed efficiency; (3) a composition for improving exercise performance in athletes, incorporating solriamfetol to enhance bioavailability in subjects with moderate renal impairment; and (4) a method for enhancing cognitive function in individuals with ADHD, administering solriamfetol in doses adapted to renal function.

Novelty and Inventive Step

The new claims introduce novel applications of solriamfetol therapy, extending its use beyond excessive daytime sleepiness and impaired renal function. The inventive concept's novelty lies in its ability to adapt solriamfetol's benefits to diverse fields, addressing unmet needs and providing innovative solutions.

Alternative Embodiments and Variations

Alternative embodiments may include integrating solriamfetol with other compounds to enhance its effects, developing targeted delivery systems for specific applications, or exploring additional industries where solriamfetol's benefits could be leveraged.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the agricultural, livestock, athletic, and cognitive enhancement industries, offering novel solutions to pressing problems and unmet needs. The market for these applications is substantial, with potential for widespread adoption and revenue growth.

Field of Art

Pharmaceutical and therapeutic applications involving drug dosing, pharmacokinetics, and physiological function optimization across medical and biological domains

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced training in pharmacology, biochemistry, and therapeutic design, capable of understanding drug metabolism, renal function interactions, and cross-domain application strategies

Obviousness Rationale

The PTD demonstrates predictable extensions of the source patent's core solriamfetol technology by applying known pharmacological principles of dose adaptation and targeted delivery across multiple domains. A PHOSITA would recognize that the fundamental mechanism of renal function-based dosing can be systematically translated to different application contexts with reasonable expectation of success. The disclosed variations represent logical extrapolations of the original therapeutic approach, utilizing standard techniques of compound adaptation and targeted formulation.

Obvious Combinations & Variations

Source Patent Element
Method of adjusting solriamfetol dosage based on renal function for treating excessive daytime sleepiness
PTD Variation
Applying similar dosage adaptation principles to agricultural crop growth and livestock feed optimization
Obviousness Reasoning
Known pharmacological principles of compound-specific dosing can be predictably applied across biological systems using standard scaling and adaptation techniques
Source Patent Element
Treating specific conditions like narcolepsy and sleep disorders using solriamfetol
PTD Variation
Extending application to cognitive enhancement and athletic performance optimization
Obviousness Reasoning
Predictable exploration of a compound's performance-modulating properties using established pharmacological research methodologies
Source Patent Element
Oral administration of solriamfetol with specific dosage considerations
PTD Variation
Developing targeted delivery systems and carrier molecules to enhance bioavailability
Obviousness Reasoning
Standard pharmaceutical engineering approach of improving drug delivery using known molecular design techniques
Source Patent Element
Therapeutic method focused on managing physiological conditions
PTD Variation
Creating sensor-based monitoring systems for detecting and preventing performance-related issues
Obviousness Reasoning
Logical combination of pharmaceutical knowledge with emerging sensor and data analysis technologies
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857528, a Person Having Ordinary Skill In The Art would find the variations disclosed in this publication to represent obvious extensions of the original solriamfetol therapeutic approach. The systematic application of renal function-based dosing principles across diverse domains demonstrates a predictable and logical progression of the source patent's core technological insights, thereby establishing robust prior art under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,528
TitleMethods of providing solriamfetol therapy to subjects with impaired renal function
Assignee(s)AXSOME MALTA LTD.